Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe you should have at least equal education in order to say the findings are correct otherwise it just sounds good.
So you have A PhD degree in Biostatistics?.
You jumped the shark on saying cure. May hold potential as all other early studies.
Also at 16:55 min: "Structural and functional MRI" is "about to be released". If all data is included with MRI then we could see full results soon.
"6:45 min: Full AD 2b/3 data is still expected this year. This will include MRI, biomarkers, blood data, dose-dependent results of ALL measures including cognition, function, quality of life."
In the words of Reagan trust but verify. Her background is physics and deal making. Good combination.
Positive peer review. B likely to improve outcomes when combined with other drugs. BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis.
BRI alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.
Taken together, these results indicate that BRI is able to potentiate CAS activity for different human fungal pathogens, including C. neoformans. Interestingly, C. neoformans is very sensitive to BRI alone and BRI is fungicidal against this fungus. Thus, BRI is an alternative therapeutic against C. neoformans alone or in combination with CAS since it potentiates the latter’s activity into a fungicidal drug. BRI?+?CAS combination has also synergism against C. auris dramatically decreasing its viability.
Great find frenchbroad.
First of all how long will it take to get new updated data. Likely newly hired Dr Jin is working on it, although frustratingly slow.
"At this time some of your questions can
not be answered today, because new,
updated data will be available to us
in the near future"
The good ol days when thumbs ups were flying.
February 23, 2023 - Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission. Go Stingray approval.
Whoa that's a huge list of nasty side effects and it was approved. If B had that long list they would be howling at the moon over it. I see tingling of the hands and feet or is it peripheral neuropathy..
That was also my thought that Parkinson's sufferers would be those at greatest risk of death from covid-19.
What stuff? You have brilacidin named in your first sentence then you go on to say stuff.
You hire a former FDA lead neurology statistician due to positive results period.
"I'm excited to welcome Dr. Jin to Anavex at this pivotal time". "Dr. Jin's deep and extensive biostatistics experience within clinical development and regulatory process will be invaluable as we advance key mid- and late-stage programs, to provide clinical and regulatory biostatistics leadership in support of Anavex’s goal to bring transformational medicines to the market."
Is this Basilea Pharmaceutica? The share price has been improving. Thanks for posting, three weeks is not far off.
"A European pharmaceutical company will discuss Brilacidin in their internal licensing meeting in 3 weeks. I know this direct from the company and not from Ipix. We will see how the Ipix stories change into the future".
Yes george h this is how I remember it. The first phase2 ABSSSI trial was at a much higher dosage which caused hypertension issues. Polymedix planned a second trial at a much lower dosage but never had a chance to implement the changes, when CTIX now IPIX picked up Brilacidin Leo and company ran the second trial using Polimedix dosage changes.
I like many take a statin so safety is a big concern but for me the good outweighs the bad.
https://blogs.webmd.com/heart-health/20210121/considering-statins-what-a-cardiologist-wants-you-to-know#:~:text=About%2035%20million%20people%20take%20statins%20in%20the,statin%20have%20more%20preventable%20heart%20attacks%20and%20strokes.
Statins for high cholesterol are among some of the worst for possible side effects but yet something like 25 million people still take them. Few people actually experience the bad ones. Seems all drugs come with some form of risk.
Leo supplies the B. Positive results reported so far in antifungal pre-clinical studies even some testing reportedly being done on animal eyeballs.
History can be a brutal reminder. It's been 8 years so yes all the ABSSSI money is down the drain. Leo progressed with OM sold us on a ABSSSI phase3 that never materialized. Those are tough facts. I'm in for BeaMed and the anti-fungal so hope springs eternal.
It's up to the science community not Leo whether B moves into a government supported clinical study or not.
My basis is in the reported. Leo reported On December 22nd 2014, Cellceutix also reported positive results in the Microbiological Intent-to-Treat (MITT) population. This is an important population that includes patients with baseline cultures positive for common ABSSSI pathogens, such as Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA). In this population, Clinical Success rates at 48-72 hours were again very high (above 90% across all treatment groups) and again very similar (with overlapping 95% confidence intervals).
The results sure sound like people being cured of their ABSSSI.
So now as frenchbroad asked, where's is the evidence that the majority experience either hypertensive crises or peripheral neuropathy?
Whats never noted is that all patience in the ABSSSI trial went home cured.
No fun going down memory lane, Kevetrin and Prurisol are history gone kaput money lost. No big pharma, small pharma not even CVS bought into it. I'm holding my shares only because I think something will come out of months of Bril testing and the BeaMed investment.
Hoping for a brighter future here.
"The thing that bugs me is that the people think the FDA is protecting them - it isn’t. What the FDA is doing and what the public thinks it’s doing are as different as night and day".
Herbert L. Ley, Jr.
FDA Commissioner 1968-1969
It seems to cause a small few to have melt downs. Go B
Whoa I like this: *We expect Basilea to renew its efforts to in-license novel anti-fungals to ensure the longevity of the franchise and believe that its in-house expertise should be a strong attraction for potential licensors.
"With the focus returning to anti-infectives, Basilea needs to re-populate its development pipeline".
B likely on Basilea's radar that's for sure. Good find.
That alone would make A-273 most favorable. Diarrhea would add to daily living struggles and cause dehydration which is dangerous for children.
Poor things seeing some brutal adverse reactions while taking trofinetide. I remember Dr Missling specifically saying diarrhea wasn't a problem with A-273.
Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
I vaguely remember seeing that statement.
And former Director of Global Science Initiatives, at the Alzheimer’s Association which is the same organization that called for FDA accelerated approval of Biogen's lecanemab. Could be a bit bias.
https://cmtrf.org/scientific-advisory-board/
No problem. Take care.
I see nothing reported since July 5 2022 where it was reported 9.92% ownership. So they still own above 5%.
So I think the answer to your question is YES medicare would welcome an oral CNS treatment over a intervenous treatment that put's the cost directly on the government to shoulder.
The thing about Aduhelm is that it's an IV not a oral delivered pharmacy drug. IV's require clinical infusion which are expensive and paid under Part B not Part D which is what pharmacy drugs are covered under. Part D pharmaceuticals think (CVS) are covered under a separate plan that participants can buy to help cover their drug costs. Part B covers 80% of costs and the patient pays 20% of costs. So with Aduhelm the full cost is charged to medicare under Part B but with an oral drug the cost is on the patient or a separate Part D insurance plan if they buy one and I think most do at some point.
Medicare is quite complicated. I bought a Medicare Advantage plan which covers meds.
Every post negative then more likely borrowed short positions. Need price to go down to make money. Not my cup of tea.
Leo and co are making headway per the latest pr.
"During the visit, BeaMed founders Moshe Eshkol and Gil Shapira provided updates on recent BeaMed progress, including a demonstration of data integration software, as well as a review of different fiberoptics undergoing rigorous testing in advance of final selection and planned submission to the U.S. FDA for marketing clearance. A tour of an onsite FDA-approved facility where the StingRay System is being manufactured was also conducted.
In other news, the Company wishes to inform shareholders that it was notified by the United States Patent and Trademark Office (USPTO) that US Patent Application 16/991812 – Host Defense Protein (HDP) Mimetics for Prophylaxis And/Or Treatment of Inflammatory Bowel Diseases of the Gastrointestinal Tract – was allowed for issuance as a patent. The claims allowed include Brilacidin treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS) and Ulcerative Colitis.
Additionally, the Company and University of São Paulo (USP), Brazil, have entered into a collaborative research agreement to investigate the broad-spectrum activity and treatment potential of Brilacidin in fungal diseases".
Thanks for posting this SitTight. Good to see more multinational studies.
Don't know but my guess is they were newer compounds with numerical names.
September 9, 2013
Cellceutix Acquires PolyMedix Assets from Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
Brilacidin
Beverly, MA — 09/09/13 — Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to announce that it has acquired substantially all of the assets of the company formerly known as PolyMedix, Inc., and previously traded as PYMX, a clinical stage biotechnology company which developed small-molecule drugs for the treatment of infectious diseases and innate immunity disorders. The acquisition includes the PolyMedix pipeline of nine compounds as well as the substantial equipment assets at PolyMedix’s 25,000-square-foot headquarters and laboratory.
IPIX acquired nine compounds.
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-acquires-polymedix-assets-from-bankruptcy-court-gains-ownership-of-two-clinical-stage-drugs-multiple-compounds-and-equipment-assets
Good to see Alfasigma trial starting second half, potential $24million in play for IPIX.